Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NTQ1062 in advanced solid tumors
NCT06172309Phase 1Completed
- Sponsor
- Nanjing Chia-Tai Tianqing Pharmaceutical
- Start
- Sep 2021
- Primary completion
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of NTQ1062 in solid tumor (advanced stage), sponsored by Nanjing Chia-Tai Tianqing Pharmaceutical. Primary endpoints: Maximum Tolerated Dose at 28 days, Recommended Phase 2 Dose at 28 days and 1 more. Started Sep 2021; status: completed.
02
Drugs
NTQ1062
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT06172309.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06172309.